News

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...
The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...
GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.
Discover 10 powerful breakfast strategies that guarantee weight loss success. Learn the best foods and combinations for ...
GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...
David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...
Plastic surgery trends show growing acceptance of aesthetic procedures as self-care, with over 28.5 million minimally ...